255 related articles for article (PubMed ID: 33059027)
1. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
[TBL] [Abstract][Full Text] [Related]
2. DLX6-AS1 is a potential biomarker and therapeutic target in cancer initiation and progression.
Zheng Q; Gu X; Yang Q; Chu Q; Dai Y; Chen Z
Clin Chim Acta; 2021 Jun; 517():1-8. PubMed ID: 33607068
[TBL] [Abstract][Full Text] [Related]
3. DLX6-AS1: a putative lncRNA candidate in multiple human cancers.
Sheykhhasan M; Ahmadyousefi Y; Seyedebrahimi R; Tanzadehpanah H; Manoochehri H; Dama P; Hosseini NF; Akbari M; Eslami Farsani M
Expert Rev Mol Med; 2021 Nov; 23():e17. PubMed ID: 34823630
[TBL] [Abstract][Full Text] [Related]
4. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
[TBL] [Abstract][Full Text] [Related]
5. A Peptide Encoded by a Long Non-Coding RNA DLX6-AS1 Facilitates Cell Proliferation, Migration, and Invasion by Activating the wnt/β-Catenin Signaling Pathway in Non-Small-Cell Lung Cancer Cell.
Xu X; Zhang Y; Wang M; Zhang X; Jiang W; Wu S; Ti X
Crit Rev Eukaryot Gene Expr; 2022; 32(8):43-53. PubMed ID: 36017915
[TBL] [Abstract][Full Text] [Related]
6. DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA.
Hu C; Liu K; Wang B; Xu W; Lin Y; Yuan C
Curr Pharm Des; 2021; 27(9):1211-1218. PubMed ID: 33121401
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells.
Wu DM; Zheng ZH; Zhang YB; Fan SH; Zhang ZF; Wang YJ; Zheng YL; Lu J
J Exp Clin Cancer Res; 2019 Jun; 38(1):237. PubMed ID: 31171015
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.
Li D; Tang X; Li M; Zheng Y
J Cell Biochem; 2019 Aug; 120(8):12290-12299. PubMed ID: 30805988
[TBL] [Abstract][Full Text] [Related]
10. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
[TBL] [Abstract][Full Text] [Related]
11. Promising long noncoding RNA DLX6-AS1 in malignant tumors.
Xue C; Lv L; Jiang J; Li L
Am J Transl Res; 2020; 12(12):7682-7692. PubMed ID: 33437353
[TBL] [Abstract][Full Text] [Related]
12. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.
Ghafouri-Fard S; Najafi S; Hussen BM; Ganjo AR; Taheri M; Samadian M
Front Cell Dev Biol; 2022; 10():746443. PubMed ID: 35281110
[TBL] [Abstract][Full Text] [Related]
13. Research progress of DLX6-AS1 in human cancers.
Luo Y; Ge P; Wang M; Chen H; Liu J; Wei T; Jiang Y; Qu J; Chen H
Hum Cell; 2021 Nov; 34(6):1642-1652. PubMed ID: 34508305
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region.
Zhao H; Xu Q
J Cell Mol Med; 2020 Nov; 24(21):12572-12584. PubMed ID: 32951317
[TBL] [Abstract][Full Text] [Related]
16. The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/β-catenin signaling pathway.
Guo J; Chen Z; Jiang H; Yu Z; Peng J; Xie J; Li Z; Wu W; Cheng Z; Xiao K
Cancer Cell Int; 2019; 19():312. PubMed ID: 31787849
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis.
Zhao P; Guan H; Dai Z; Ma Y; Zhao Y; Liu D
Eur J Pharmacol; 2019 Dec; 865():172778. PubMed ID: 31705901
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer.
You Q; Shi HY; Gong CF; Tian XY; Li S
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6429-6435. PubMed ID: 31378881
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1.
Li X; Zhang H; Wu X
Gene; 2019 Feb; 686():1-7. PubMed ID: 30366080
[TBL] [Abstract][Full Text] [Related]
20. Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer.
Ding XZ; Zhang SQ; Deng XL; Qiang JH
Technol Cancer Res Treat; 2021; 20():1533033821990060. PubMed ID: 33550924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
